US · QNTM
Quantum BioPharma Ltd.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Toronto, ON M5J 2H7
- Website
- quantumbiopharma.com
Price · as of 2024-12-31
$5.55
Market cap 13.64M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $2,586.87 | $37,671.52 | |||
| 2019 | $279.11 | ||||
| 2020 | $133.25 | ||||
| 2021 | $59.15 | ||||
| 2022 | $94.25 | ||||
| 2023 | $52.65 | ||||
| 2024 | $4.62 |
AI valuation
Our deep-learning model estimates Quantum BioPharma Ltd.'s (QNTM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.55
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| QNTM | Quantum BioPharma Ltd. | $5.55 | 13.64M | — | — | — | — | -0.35 | 0.46 | — | 0.08 | — | 0.80 | 0.00% | — | — | -120.69% | -212.74% | -86.23% | 0.07 | -339.16 | 1.80 | 1.65 | 0.36 | -5750.00% | — | -3649.00% | -130.92% | -1.03 | -90.66% | 0.00% | 0.00% | 52.41% | 0.07 | 0.16 | — | -16.34 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| CPIX | Cumberland Pharmaceutical… | $4.92 | 73.59M | +2,442% | -39% | — | — | -13.82 | 3.92 | 2.37 | 505.27 | -304.09 | 22.58 | 82.61% | -16.99% | -17.11% | -24.71% | -23.24% | -8.24% | 0.90 | -10.62 | 1.15 | 0.94 | 14.30 | 455.00% | -426.00% | -11404.00% | -0.88% | -0.02 | -2.87% | 0.00% | 0.00% | 0.65% | -14.33 | -116.39 | 2.43 | 0.87 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RMTI | Rockwell Medical, Inc. | $0.90 | 35.49M | +8,164% | -8% | +5% | — | -104.82 | 1.54 | 0.50 | 14.30 | — | 2.34 | 17.23% | 0.60% | -0.47% | -1.78% | 2.52% | -0.86% | 0.42 | 0.48 | 2.63 | 2.12 | -0.72 | -9300.00% | 2138.00% | -13291.00% | 6.34% | 0.30 | 13.21% | 0.00% | 0.00% | 13.08% | 69.49 | 13.24 | 0.42 | -6.06 |
| RNTX | Rein Therapeutics Inc. | $1.14 | 29.97M | — | — | — | — | -0.57 | 0.66 | — | -0.81 | -21.57 | 6.09 | 0.00% | — | — | -205.24% | -408.03% | -71.76% | 0.00 | — | 2.38 | 2.24 | 0.46 | 263.00% | — | 1254.00% | -62.45% | -3.88 | -143.12% | 0.00% | 0.00% | 0.00% | -0.35 | -1.02 | — | -8.63 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
- CEO
- Zeeshan Saeed
- Employees
- 0
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.55) − 1 = — (DCF, example).